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JACC Febnmn I~FJX AF!.~TRA('I'.~ (~d I¢~IA 
surgery (1-72), Them has been no late death, In Conclusion, com~tetion 
Fonten using an extmcardtac conduit w~thout CPB may be achievE~l with 
gratifying results, In the last 7 patients the Itv~mg~ rmspitel ength of stay 
was 7 d~y~ with an ICU stay ot 3, Any advnntago over mere conventmnal 
methods using CPB remains 1o be proven, 
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~ Ab¢ lx lmab ( f lNPro)  Potm~llMtm Thmmboly=!~ In ST 
Ekn~t lon  Myocardial Infan,'tion: Rtmu,'t= o1TIMI t4  
EM, An~,  R,P. ~ano.  C.H ~ ,  M G i~,  AJJ, Adgey, 
M Ghall, P Coussemi~l, KM A~fson,  J, Schare~, F. Van de Wed, 
E, Braunwald, ~ the TIMt '/4 Invesr~atots. ~z~ttam and P,~men~ 
HOS~!at. Boston. M& US4 
TO delemtme whe~ lhe ptatelet GPIIb/llla receplor antagonist abommab 
enhances thfombofysts, the TIMI 14 IP.al is ~ patmofs w~th ~ ? 
MI < 12 h ol ~ to fecewe: accelerated full dose IPA versus ReoPro 
(bolus 0.25 mg~g. infusion 0 125 ~,g;kg/n~n . 12 h) atone or with reduced 
doses el 5trept~mase (SK) or tPA~ All palmnts receNe esl~,n (150-325 
rag) and belPann (aPTT 50-70 s), Results to date in me dose lin~ng phase 
(groups of 35 pts) are: 
~ :  IPA ReoPro SK+ReoPro tPA.ReoPro 
ReoPm + * * * ,. 
SK(U, t0% - - 500 750 - - 
tPA (rag) tOO - - 20 35 
TIM.I 3 ffo~ (90 rrvn) 60% 31% 42% 37% 55% 71% 
Ma~or Hemowhage (%) 5 6 6 8 6 0 
Other doses ol lyres to be tested w~th a.~x:tximab incfu(k~ 1.25 MUSK 
and 50 mg tPA. The. oefireum regimen(s) w~!l then be evaluated in a dose 
coof!rmabon phase. 
Concfus~on: In ST I MI. platslet inhibdlon alone with abcix~mab does 
not achieve desirable levels of TIMI 3 flow. However. it has a syner~ic 
effect with markedly [educed doses of thrembolytms, prodacmg flow rates 
as high as tho~e obtained with conventional doses of SK or tPA In the 
regimens tested to date, this apears to be accomplished without an increase 
in bleeding ask, suggesting that abctximab and low dose thmmboly1~cs may 
be an attrachve new approach to repertus=on 
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~8"-~"] Survival Benefit  of Abc ix lmab During Administration 
Early Rescue Angioplasty: Analysis of 387 Patients 
From the GUSTO-Ill Trial 
JM. Miller. EM. Ohman, J.S. Scbltdcrout, R.W. Smallmg, A. Betnu. 
RM Calift. E.J. Topoi. Duke University Medical Center, Durham. NC. USA 
Background and Methods: Abciximab (c7E3) reduces ischemic events after 
high-risk and elective PTCA. but its nsks and benefits during rescue angio- 
plasty are uncertain. We evaluated 387 pts who had PTCA of the IRA -:24 
h after receiving thrombolytic therapy (median 3.5 h). 81 pts received c7E3 
while 306 did not. 
ReSultS: Pts given c7E3 were similar in age and gender, compared with 
the non..cTE3 group. Pts given c7E3 were less likely to have antenor MI 
location (37% vs 52%, p = 0.02), but were more often Killip class III or IV (8% 
vs 2%, p = 0.01). 
Abctximab No abciximab P 
Pro-PTCA TIMI 0-1 40 170) 136 (61%) 
Intractanial b eed 0 2 (07) 
Moderate bleed 13 t16) 45 (15) 
Severe bleeding 3 (3.7) 3 (10) 008 
30-d Mortahty 3 (37) 30 i9.8) 004" 
( ) = % "Adjusted for baseline differences 
Among c7E3 pts, r.PA+ c7E3 had a lower combined endpoint of death, 
MI, stroke (8% vs 21%. p = 0.07) compared with t-PA+ c7E3. 
Conclusion: Selective use of c7E3 in pts undergoing rescue PTCA is 
associated with lower 30 day mortality, with a modest increase in bleeding. 
Future studies should explore the appropriate dose of fibrinolytic, heparin 
end c7E3 to further improve the survival in acute ML 
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84~_ .~ Combined Therapy With $ t~ptok inau  and Inllsgdlin 
E Ronner, HAM van Kestemn, P Zilnen, U Tebbe, P Mott~ek, C Curie, 
E Velte, T~ Lorenz, K Ne,Jn~us, ML  S~moons T~xc~n~t, E',=~m~ 
Un~vers;l~, Rolferdam, Th~ 
Expenmentat =ludtes have sho~n improved ¢t0t lysla t~y com~m~m ol 
thrombolyti¢ th@mpY ar~l IpIatelet GP IIb.lllP, receptor ~kef~ ~ we 
m~se (1,500,000 units) and I~ lm,  a compet~bve II~l!lzt blocker m 
presenting wllh i~ule ~ t  infa~orl, lntegn!m wM a~av, stefe¢l 8s iv 
bolus of 180 ~g~g followed by an m ~  of 0?5, t.33 of ;L0 ~di&gtmm, 
Patients were random~ed to ~ doses or Io placebo (r~=o 2:1) m an 
~sc-.al~tmg n~nner. 
The ~ghast dose an~ was d~;'ontinued when an ~¢mased 
rate was obs~n~l~ Them were no inlrao~r~a! hemorrhages, and the vast 
m, aionty of t~ng was from ~rtena! pu~tum s~tes, Comnan/angmgrams 
were per fo~ 90 mlnute~ afte¢, i~tiatmn Of s1~inase  and Sludy drug 
tO assess T!MI grade flow. Results from 171 of 18t patmnl~ ra~zeO fs 
del:.cled below: 
Inl~td~n 
Placebo 180~ 75 tSO/1 33 I SO~20 
Patients In) 59 43 42 27 
TIMI flo~ 0-1 (%) 38 22 27 12 
2 (%l 27 25 29 3~ 
3 (%~ 38 53 44 52 
Breedrng n~ne t%) 75 53 29 33 
mild (%) 22 30 31 25 
mod/sev (%) 3 16 40 40 
REIC Transfusion (%) 0 12 12 19 
Comb0ned therapy w~h streptokinase and Integfllin in patients with evolv. 
ing myocardial infarctmn ymlde¢l a modest increase m early (90 minutes) 
TIMI grade 3 flow compared with slreptokinase and placebo However, this 
combna~on was also asso~ated wTth an increase m btee~ng, pamculady 
at the higher doses tested. Combination of full dose streptokinase and the 
higher doses of lnteg~lm used in thrs study should he avoided. Evaluation 
Of other dose regrmens of (other) ff~romOohr~ca and Integnlin is warranted to 
obtain increased mparfusmn rates wdhout increasing the nsk of bteeckng. 
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-~-~ Low Weight Heparin Molecular Versus 
Unfractionated Heparln Following Thrombolysls in 
Myocardial Infarct ion 
SH Baird, SJ. Mc Bnde. TG Trouton, C. Wilson Anfnm Area Hospital, 
An~nm. UI'( 
Backgcound: Optimal adjuvant therapy following thrombolysls for acute my- 
ocardial infarction [AMI) remains an unresolved issue although intravenous 
ur~fractionated hep~rin (UFH) is commonly used. We compared the use of 
low molecular weight heparm (LMWH) w=th UFH following thrombofysts, 
Methods: Three hundred patie~s treated wllh thrombolysis for AMI were 
randomly assigned LMWH as enoxapann (40 mg LV. initially, then 40 mg 8 
hourly subcutaneously, n = 149) or UFH (30,000 units daily by contimmus 
Lv. infusmn, n = 151) for 4 days in conjunction with routine therapy. The 
groups were s~milar in relation to age. sex, peak serum cmatinine kinase, 
thrombolytic agent used and use of beta blockers and aspmn. 
Results: Companson of signifcant cardiac events in the patient groups 
mcewing LMWH or UFH over 3 months follow up was as follows: death from 
cardiac cause occurred in 9 vs. 16 patients (p = 0.15); non fatal reinfarction 
22 vs. 30 patients (p = 0.24): readmiss~on with a diagnosis of cardiac pain 
without infarcbon 7 vs. 9 patients (p = 0.62). Combining these end-points, 38 
patients (26%) in the LMWH group vs. 55 patients (3~'=) in the UFH group 
sustained a cardiac event dunng follow up (p = 0.04). Reinfaretion in the 48 
hours after discontinuation of study drug was significantly less frequent for 
LMWH than UFH (3 vs. 10 patients, p = 0.05). The frequency of clinically 
significant haemorrhage was stm=lar in the two groups 
Conclusion: The use of LMWH renewing thrombotysts =s afe and effectwe, 
significantly reducing further cardfac events. 
